Europe's drugs regulator said on Tuesday it is evaluating the use of remdesivir in COVID-19 patients who do not need oxygen support, after developer Gilead Sciences submitted an application to extend the medicine's use.
Europe had conditionally approved remdesivir, sold under the brand name Veklury, in July for treating COVID-19 in adults and adolescents with pneumonia requiring oxygen support.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.